L’Oreal (OTCMKTS:LRLCY – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Valuation and Earnings
This table compares L’Oreal and Dermata Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| L’Oreal | $49.83 billion | 4.82 | $6.93 billion | N/A | N/A |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($4.39) | -0.37 |
Insider and Institutional Ownership
0.4% of L’Oreal shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for L’Oreal and Dermata Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| L’Oreal | 1 | 4 | 7 | 1 | 2.62 |
| Dermata Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
L’Oreal currently has a consensus target price of $100.00, indicating a potential upside of 10.91%. Given L’Oreal’s stronger consensus rating and higher possible upside, equities research analysts plainly believe L’Oreal is more favorable than Dermata Therapeutics.
Profitability
This table compares L’Oreal and Dermata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| L’Oreal | N/A | N/A | N/A |
| Dermata Therapeutics | N/A | -166.66% | -130.13% |
Risk & Volatility
L’Oreal has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
Summary
L’Oreal beats Dermata Therapeutics on 9 of the 11 factors compared between the two stocks.
About L’Oreal
L'Oréal S.A., through its subsidiaries, manufactures and sells cosmetic products for women and men worldwide. The company operates through four divisions: Consumer Products, L'oréal Luxe, Professional Products, and Dermatological Beauty. It offers skincare, make-up, hair colourants, haircare, perfumes, and hygiene products. The company provides its products under the L'Oréal Paris, Garnier, Maybelline New York, NYX Professional Makeup, Stylenanda, Essie, Dark & Lovely, Mixa, Magic Mask, Niley, Lancôme, Yves Saint Laurent, Armani, Kiehl's Since 1851, Helena Rubinstein, Biotherm, Shu Uemura, IT Cosmetics, Ralph Lauren Fragrance, Urban Decay, Mugler, Valentino, Viktor&Rolf, Azzaro, Prada, Cacharel, Maison Margela Fragrance, Diesel, Yue Sai, Atelier Colonge, Carita, Takami, Aesop, L'Oréal Professionnel Paris, Kérastase, Redken, Matrix, Pureology, Pulp Riot, La Roche-Posay, Vichy, CeraVe, SkinCeuticals, and Skinbetter Science brands. It sells its products through distribution channels, such as hair salons, local stores, e-commerce, travel retail, mass market retail, department store perfumeries, pharmacies, drug stores, medi-spas, and free-standing stores. L'Oréal S.A. was founded in 1909 and is headquartered in Clichy, France.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for L'Oreal Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for L'Oreal and related companies with MarketBeat.com's FREE daily email newsletter.
